# Filing Detail

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001129928-22-000017
Filing Date
2022-03-03
Accepted
2022-03-03 16:55:08
Documents
126
Period of Report
2021-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 20-F | oncyf-20211231.htm iXBRL | 20-F | 2218394
2 | EX-1.1 | articles.htm | EX-1.1 | 19538
3 | EX-1.2 | ex12onc-2017byxlaws1636459.htm | EX-1.2 | 44800
4 | EX-2.1 | ex21exdescriptionofsecurit.htm | EX-2.1 | 3136
5 | EX-4.18 | ex418mattcoffeyamendment3-.htm | EX-4.18 | 14375
6 | EX-4.19 | ex419kirklookamendment3-em.htm | EX-4.19 | 14450
7 | EX-4.20 | ex420allisonhagermanamendm.htm | EX-4.20 | 14991
8 | EX-4.21 | ex421andrewdeguttadauroame.htm | EX-4.21 | 14794
9 | EX-4.22 | ex422thomasheinemanamendme.htm | EX-4.22 | 22091
10 | EX-8.0 | ex80subsidiaries2021.htm | EX-8.0 | 3624
11 | EX-12.1 | ex121ceocertification2021.htm | EX-12.1 | 9912
12 | EX-12.2 | ex122cfocertification2021.htm | EX-12.2 | 9682
13 | EX-13.1 | ex131ceocertification2021.htm | EX-13.1 | 5139
14 | EX-13.2 | ex132cfocertification2021.htm | EX-13.2 | 4776
15 | EX-15.1 | ex151-2021mda.htm | EX-15.1 | 399076
16 | EX-15.2 | ex152ey2021consent.htm | EX-15.2 | 6414
17 |  | articles001.jpg | GRAPHIC | 193024
18 |  | articles002.jpg | GRAPHIC | 131925
19 |  | articles003.jpg | GRAPHIC | 164242
20 |  | articles004.jpg | GRAPHIC | 189812
21 |  | articles005.jpg | GRAPHIC | 238635
22 |  | articles006.jpg | GRAPHIC | 163182
23 |  | articles007.jpg | GRAPHIC | 278217
24 |  | articles008.jpg | GRAPHIC | 198799
25 |  | articles009.jpg | GRAPHIC | 159530
26 |  | articles010.jpg | GRAPHIC | 159006
27 |  | articles011.jpg | GRAPHIC | 106912
28 |  | articles012.jpg | GRAPHIC | 225065
29 |  | oncolyticslogotaglinebluea.jpg | GRAPHIC | 367326
30 |  | oncyf-20211231_g1.jpg | GRAPHIC | 148102
31 |  | oncyf-20211231_g2.jpg | GRAPHIC | 460603
32 |  | oncyf-20211231_g3.jpg | GRAPHIC | 6561
33 |  | eyheadera.jpg | GRAPHIC | 2717
| Complete submission text file | 0001129928-22-000017.txt |  | 14586853

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
34 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | oncyf-20211231.xsd | EX-101.SCH | 78426
35 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | oncyf-20211231_cal.xml | EX-101.CAL | 45427
36 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | oncyf-20211231_def.xml | EX-101.DEF | 281203
37 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | oncyf-20211231_lab.xml | EX-101.LAB | 655121
38 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | oncyf-20211231_pre.xml | EX-101.PRE | 449588
120 | EXTRACTED XBRL INSTANCE DOCUMENT | oncyf-20211231_htm.xml | XML | 1566485

Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-38512 | Film No.: 22709926
SIC: 2834 Pharmaceutical Preparations